EUCTR2015-005781-39-RO进行中（未招募）1 期
A Phase 3b/4, Prospective, Multicenter, Open-label, Randomized, Crossover Study of Tolerability and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients with Hemophilia A or B with Inhibitors - FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. = 18 to = 65 years old at the time of screening
- •2. Hemophilia A or B of any severity, with a documented = 3 months history of inhibitors (= 0.6 BU) requiring the use of bypassing agents (FEIBA or rFVIIa) prior to screening. Inhibitor level will be tested at screening if no documented history is available.
- •3. Hepatitis C virus (HCV) negative, either by antibody testing or polymerase chain reaction (PCR); or HCV positive with stable liver disease
- •4. Human immune deficiency virus (HIV) negative; or HIV positive with stable disease and CD4 count = 200 cell/mm3 at screening
- •5. Adequate venous access
- •6. Willing and able to comply with the requirements of the protocol
- •7. If a female of childbearing potential, must have a negative blood pregnancy test and agrees to employ adequate birth control measures for the
- •duration of the study, such as:
- •a. Abstain from sexual intercourse
- •b. Use a reliable method of contraception (contraception such as an intrauterine device, barrier method [e.g., diaphragm or sponge; female condom not permitted] with spermicide, oral contraceptive, injectable progesterone, sub dermal implant), and have their male partner use a condom
- •8. If female of non-childbearing potential, confirmed at screening by fulfilling 1 of the following criteria:
- •a. Postmenopausal, defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and with follicle-stimulating hormone levels within the laboratory-defined postmenopausal range or postmenopausal with amenorrhea for at least 24 months and on
- •hormonal replacement therapy
- •b. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, bilateral tubal ligation (with no subsequent
- •pregnancy at least 1 year from bilateral tubal ligation), or bilateral salpingectomy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Known hypersensitivity to FEIBA or any of its components
- •2. Advanced liver disease (e.g., liver biopsy confirmed diagnosis of cirrhosis, portal vein hypertension, ascites, prothrombin time [PT] 5 seconds above upper limit of
- •3. Planned elective surgery during participation in this study (excluding minor procedures that will not need preventative bleeding treatments, such as exchanges of peripherally inserted central catheters)
- •4. Platelet count < 100,000/µL
- •5. Taking Emicizumab (Hemlibra) for bleed prevention
- •6. Clinical or laboratory evidence of disseminated intravascular coagulation based on medical history
- •7. Prior history or evidence of thromboembolic event: acute myocardial infarction, deep vein thrombosis, pulmonary embolism, etc.
- •8. Diagnosis of advanced atherosclerosis, malignancy, and/or other diseases that may increase the subject’s risk of thromboembolic complications
- •9. Taking any immunomodulating drug (e.g., corticosteroid agents at a dose equivalent to hydrocortisone > 10 mg/day, or a-interferon) within 30 days prior to enrollment except anti-retroviral chemotherapy.
- •10. Herbal supplements that contain anti-platelet activity
- •11. Subject has participated in another clinical study involving an IP or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
- •12. Family member or employee of the investigator
- •13. Clinically significant medical, psychiatric or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject safety or compliance
研究者
相似试验
进行中（未招募）
1 期
A Study of the Safety and Tolerability of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients with Hemophilia A or B with InhibitorsHemophilia A or B with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2015-005781-39-HRBaxalta Innovations GmbH32
招募中
3 期
A clinical trial to study the percentage of subjects in complete (clinical and endoscopic) remission after 12 months of maintenance treatment with 2.4g/day MMXmesalamine/mesalazine given once daily (QD) between subjects who were in complete remission and subjects who were in partial remission at the end of 8 weeks acute treatment with 4.8g/day MMX mesalamine /mesalazine given QD.CTRI/2010/091/001221Shire Development Inc.725 Chesterbrook BoulevardWayne, Pennsylvania 19087,695
进行中（未招募）
不适用
A Study to Evaluate the Ability to Maintain Clinical and Endoscopic Remission During a 12-Month period with 2.4g/day of drug given once a day in adults with ulcerative colitislcerative ColitisMedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2009-017044-13-HUShire Development LLC1,000
进行中（未招募）
不适用
A study to Evaluate the Ability to Maintain Clinical andEndoscopic Remission During a 12-Month period with 2.4g/day of druggiven once a day in adults with ulcerative colitislcerative ColitisMedDRA version: 14.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2009-017044-13-IEShire Development LLC1,000
进行中（未招募）
1 期
A study to Evaluate the Ability to Maintain Clinical and Endoscopic Remission During a 12-Month period with 2.4g/day of drug given once a day in adults with ulcerative colitisEUCTR2009-017044-13-BEShire Development LLC1,000